Tuberculous Meningitis: Diagnosis and Treatment Overview by Marx, Grace E. & Chan, Edward D.
Hindawi Publishing Corporation
Tuberculosis Research and Treatment
Volume 2011, Article ID 798764, 9 pages
doi:10.1155/2011/798764
Review Article
TuberculousMeningitis:Diagnosis and TreatmentOverview
GraceE.Marx1 andEdwardD.Chan1,2,3,4,5
1Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA
2Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver Anschutz Medical Campus,
Aurora, CO 80045, USA
3Denver Veterans Aﬀairs Medical Center, Denver, CO 80220-3808, USA
4Department of Medicine, National Jewish Health, Denver, CO 80206, USA
5Program in Cell Biology, National Jewish Health, Denver, CO 80206, USA
Correspondence should be addressed to Edward D. Chan, chane@njc.org
Received 3 September 2011; Revised 16 November 2011; Accepted 18 November 2011
Academic Editor: Carlo Garzelli
Copyright © 2011 G. E. Marx and E. D. Chan. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Tuberculousmeningitis(TBM)isthemostcommonformofcentralnervoussystemtuberculosis(TB)andhasveryhighmorbidity
and mortality. TBM is typically a subacute disease with symptoms that may persist for weeks before diagnosis. Characteristic
cerebrospinal ﬂuid (CSF) ﬁndings of TBM include a lymphocytic-predominant pleiocytosis, elevated protein, and low glucose.
CSF acid-fast smear and culture have relatively low sensitivity but yield is increased with multiple, large volume samples. Nucleic
acid ampliﬁcation of the CSF by PCR is highly speciﬁc but suboptimal sensitivity precludes ruling out TBM with a negative test.
Treatment for TBM should be initiated as soon as clinical suspicion is supported by initial CSF studies. Empiric treatment should
include at least four ﬁrst-line drugs, preferably isoniazid, rifampin, pyrazinamide, and streptomycin or ethambutol; the role of
ﬂuoroquinolones remains to be determined. Adjunctive treatment with corticosteroids has been shown to improve mortality with
TBM. In HIV-positive individuals with TBM, important treatment considerations include drug interactions, development of
immune reconstitution inﬂammatory syndrome, unclear beneﬁt of adjunctive corticosteroids, and higher rates of drug-resistant
TB. Testing the eﬃcacy of second-line and new anti-TB drugs in animal models of experimental TBM is needed to help determine
the optimal regimen for drug-resistant TB.
1.Introduction
Tuberculous meningitis (TBM) is caused by Mycobacterium
tuberculosis (M. tuberculosis) and is the most common form
of central nervous system (CNS) tuberculosis (TB). TBM is
associated with a high frequency of neurologic sequelae and
mortality if not treated promptly [1–5] .T B Mi sr a r ei nd e -
veloped countries with about 100 to 150 cases occurring
annually in the US, less than 3% of the estimated 4,100 an-
nual cases of bacterial meningitis [6, 7]. The disease occurs
when subependymal or subpial tubercles, also known as
“Rich foci” seeded during bacillemia of primary infection or
disseminated disease, rupture into the subarachnoid space
[8]. Individuals with increased risk for TBM include young
children with primary TB and patients with immunodeﬁ-
ciency caused by aging, malnutrition, or disorders such as
HIVandcancer[9,10].Theuseofantitumornecrosisfactor-
alpha (TNFα) neutralizing antibody has also been associated
with increased risk of extrapulmonary TB including TBM
[11]. Most have no known history of TB, but evidence of
extrameningeal disease (e.g., pulmonary) can be found in
about half of patients [3, 4]. The tuberculin skin test is posi-
tiveinonlyabout50%ofpatientswithTBM.InlowTBprev-
alence areas, TBM is most commonly seen with reactivation
TB.
2.ObjectiveandMethod
T h eg o a lo ft h i so v e r v i e wi st od e s c r i b ee v i d e n c e - b a s e d
diagnostic and treatment approaches of TBM. This paper
was written for clinicians seeking a practical summary of
this topic. While this paper focuses on these aspects of TBM,2 Tuberculosis Research and Treatment
a brief overview of the clinical manifestations of TBM as well
as past and current animal models of TBM treatment will be
discussed.
Literature in this ﬁeld was systematically identiﬁed on
PubMed using the key words “tuberculous meningitis,” “tu-
berculosis cerebrospinal ﬂuid,” and “tuberculosis nervous
system,” as well as combing through the bibliography of rel-
evant papers. More recent articles describing new ﬁndings in
the ﬁeld were given particular attention.
3. ClinicalManifestations
TBM is typically a subacute disease. In one seminal review,
symptoms were present for a median of 10 days (range, one
day to nine months) prior to diagnosis [4]. A prodromal
phase of low-grade fever, malaise, headache, dizziness, vom-
iting, and/or personality changes may persist for a few weeks,
after which patients can then develop more severe headache,
alteredmentalstatus,stroke,hydrocephalus,andcranialneu-
ropathies. Seizures are uncommon manifestations of TBM in
adults and when present should prompt the clinician to con-
sider alternate diagnoses such as bacterial or viral meningitis
or cerebral tuberculoma; in contrast, seizures are commonly
seen in children with TBM, occurring in up to 50% of pedi-
atric cases [12]. The clinical features of TBM are the result of
basilar meningeal ﬁbrosis and vascular inﬂammation [13].
Classic features of bacterial meningitis, such as stiﬀ neck
and fever, may be absent. When allowed to progress without
treatment, coma and death almost always ensue. In survivors
of TBM, neurologic sequelae may occur that include mental
retardation in children, sensorineural hearing loss, hydro-
cephalus, cranial nerve palsies, stroke-associated lateralizing
neurological deﬁcits, seizures, and coma [14].
4.Diagnosis
The diagnosis of TBM can be diﬃcult and may be based only
on clinical and preliminary cerebrospinal ﬂuid (CSF) ﬁnd-
ings without deﬁnitive microbiologic conﬁrmation. Certain
clinical characteristics such as longer duration of symptoms
(>six days), moderate CSF pleiocytosis, and the presence of
focal deﬁcits increase the probability of TBM [15, 16]. Char-
acteristic CSF ﬁndings of TBM include the following:
(i) lymphocytic-predominant pleiocytosis. Total white
cell counts are usually between 100 and 500 cells/μL.
Very early in the disease, lower counts and neutrophil
predominance may be present,
(ii) elevated protein levels, typically between 100 and
500mg/dL,
(iii) low glucose, usually less than 45mg/dL or CSF: plas-
ma ratio <0.5.
CSF sample should be sent for acid-fast smear with the
important caveat that a single sample has low sensitivity, on
the order of 20%–40% [17]. Several daily large volume (10–
15mL) lumbar punctures are often needed for a microbi-
ologic diagnosis; sensitivity increases to >85% when four
spinal taps are performed [18]. Early studies demonstrated
that acid-fast stains can detect up to 80% [18] although
results are highly dependent on CSF volume, timeliness of
sample delivery to the lab and analysis, and the technical
expertise of lab personnel. While culture can take several
weeks and also has low sensitivity (∼40–80%), it should be
performed to determine drug susceptibility. Drug-resistant
strains have important prognostic and treatment implica-
tions; indeed, TBM due to isoniazid- (INH-) resistant M.
tuberculosis strains have been associated with a twofold in-
crease in mortality [19].
Given the relatively low sensitivity of acid-fast smear and
inherentdelayinculture,newerdiagnosticmethodsforTBM
have been more recently developed [17]. Although ELISA
assays have been developed to detect antibodies directed
against speciﬁc mycobacterial antigens in the CSF with vary-
ing sensitivities, their limited availability precludes their use
as point-of-care tests in resource-poor countries [17, 20].
A recent study in children aged 6–24 months suggests that
a CSF adenosine deaminase level of ≥10U/L has >90%
sensitivity and speciﬁcity of diagnosing TBM [21]. However,
other studies have shown poor speciﬁcity of adenosine
deaminase for TBM in certain populations, particularly in
HIV-infected adults with concurrent infections or cerebral
lymphomas [22].
Comparison of microscopy/culture of large CSF volumes
to nucleic acid ampliﬁcation (NAA) has shown that sensitiv-
ity of these methods for the diagnosis of TBM is similar [23].
A meta-analysis determined that commercial NAA assays
utilizing polymerase chain reaction (PCR) for the diagnosis
of TBM had an overall sensitivity of 56% and a speciﬁcity
of 98% [24]. The surprisingly poor sensitivity is likely due
to the fact that most PCR-based studies use a single target for
ampliﬁcation whichcanresultin false-negativeresultsdueto
theabsenceofthetargetgeneinsomeTBisolates[25].Newer
PCR tests amplify several target genes simultaneously and
have been shown to result in much higher sensitivities in the
range of 85%–95% [26]. Currently, most experts conclude
thatcommercialNAAtestscanconﬁrmTBMbutcannotrule
itout[27].Thus,itbearsemphasizingthatanegativeCSFex-
aminationforacid-fastbacilliorM.tuberculosisDNAneither
excludes the diagnosis of TBM nor obviates the need for
empirictherapyiftheclinicalsuspicionishigh.Afterstarting
treatment, the sensitivity of CSF smear and culture decreases
rapidly, while mycobacterial DNA may be detectable in the
CSF for up to a month after treatment initiation [28].
Diagnosis of TBM can be helped by neuroimaging. Clas-
sic neuroradiologic features of TBM are basal meningeal en-
hancement and hydrocephalus [17]. Hypodensities due to
cerebral infarcts, cerebral edema, and nodular enhancing le-
sionsmayalsobeseen.Magneticresonanceimaging(MRI)is
the imaging test of choice for visualizing abnormalities asso-
ciated with TBM, as it is superior to computed tomography
(CT)forevaluating the brainstemandspine. TheT2-weight-
ed MRI imaging has been shown to be particularly good at
demonstrating brainstem pathology; diﬀusion-weighted im-
aging(DWI)isbestatdetectionofacutecerebralinfarctsdue
to TBM [29]. However, CT is adequate for urgent evaluation
of TBM-associated hydrocephalus for possible surgical inter-
vention.Tuberculosis Research and Treatment 3
5. Treatment
5.1. Antimicrobial Therapy. Timely treatment dramatically
improves the outcome of TBM. Thus, empiric treatment is
warranted when clinical features and CSF ﬁndings are sug-
gestive of TBM even before microbiologic conﬁrmation. The
recommendedtreatmentregimenforpresumeddrugsuscep-
tible TBM consists of two months of daily INH, rifampin
(RIF), pyrazinamide (PZA), and either streptomycin (SM),
or ethambutol (EMB), followed by 7–10 months of INH and
RIF(Table 1)[17,30–34].INHisconsideredthemostcritical
of the ﬁrst-line agents due to its excellent CSF penetration
and high bactericidal activity (Table 2)[ 35–39]. While RIF
penetrates the CSF less freely, the high mortality of TBM due
to RIF-resistant strains has conﬁrmed its importance [40].
PZA has excellent penetration into the CSF and is a key drug
in reducing the total treatment time for drug-susceptible TB
[41].Hence,ifPZAcannotbetolerated,thetreatmentcourse
for TBM should be lengthened to a total of 18 months. While
SMorEMBaretraditionallyusedasthefourthanti-TBagent
in TBM, neither penetrates the CSF well in the absence of
inﬂammation and both can produce signiﬁcant toxicity with
long-term use [41]. It bears emphasizing that not only the
choice of antimicrobials, but also the dose used and duration
of treatment are empiric in TBM and largely based on the
treatment of pulmonary TB.
Giventhatthenewergenerationﬂuoroquinolones(FQN),
for example, levoﬂoxacin and moxiﬂoxacin, have strong ac-
tivity against most strains of M. tuberculosis and have excel-
lent CSF penetration and safety proﬁles, FQN would appear
to have great potential as part of ﬁrst-line therapy for TBM.
In a randomized controlled study for TBM treatment, addi-
tion of an FQN to standard regimen enhanced anti-TB per-
formance as measured by various clinical parameters. Al-
though there was no signiﬁcant diﬀerence in mortality, the
study waslikely not adequatelypowered to demonstrate such
an eﬀect [38]. It is important to note that serum FQN con-
centrations are lowered by concurrent RIF use; furthermore,
the optimal area-under-the-curve to minimum inhibitory
concentration ratio for FQN as anti-TB agents has not been
well described. Another randomized controlled study is cur-
rently underway to evaluate treatment of TBM with high-
dose RIF and levoﬂoxacin compared to standard treatment
[42]; if they have positive results, the recommended standard
treatment may change in the near future.
No controlled trials have been published to date for the
treatment of multidrug resistant (MDR) TBM, deﬁned as
resistance to at least INH and RIF. Furthermore, very few
studies have been published on the CSF penetrance of many
of the second-line and newer anti-TB agents. Clinicians of
patients with MDR-TBM are left to extrapolate from guide-
lines for the treatment of pulmonary MDR-TB. The World
Health Organization recommends for pulmonary MDR-TB
the use of a minimum of four agents to which the M. tuber-
culosis strain has known or suspected susceptibility including
use of any ﬁrst-line oral agents to which the strain remains
susceptible, an injectable agent (i.e., an aminoglycoside or
capreomycin), an FQN, and then adding other second-line
agents as needed for a total of at least four drugs [34]. CSF
penetration of the ﬁrst- and second-line anti-TB drugs are
shown in Table 2 [35, 43–49].
Among new anti-TB agents, bedaquiline (TMC207, a di-
arylquinoline) and delamanid (OPC-67683, a nitro-di-hy-
droimidazo-oxazole) appear most promising, as they are
both in phase III clinical trials [50]. Three additional novel
agents, sudoterb (LL3858, a pyrrole derivative), PA-824 (a
nitroimidazo-oxazine),andSQ109(ananalogueofEMB)are
currently in phase II trials [50, 51]. Their ability to penetrate
the CSF has yet to be adequately studied (Table 2).
5.2. Adjunctive Corticosteroid Therapy. Much of the neuro-
logic sequelae of TBM is considered to be due to an overexu-
berant host-inﬂammatory response that causes tissue injury
and brain edema [52]. Since the middle of the 20th century,
systemic corticosteroids have been used as adjunctive treat-
ment for TBM on the basis of the notion that dampening of
the inﬂammatory response can lessen morbidity and mortal-
ity, a reasonable hypothesis as the brain is conﬁned to a
ﬁxed space. Indeed, adjunctive corticosteroid treatment of
pyogenic bacterial meningitis has shown eﬃcacy in certain
groups of patients [53, 54] although this is controversial [55,
56]. In attempting to determine the cell type responsible for
incitingtheinﬂammatoryresponse,Rocketal.[2]foundthat
M. tuberculosis was much more likely to infect brain tissue
macrophages(microglialcells)withmarkedincreasesinpro-
duction of proinﬂammatory cytokines and chemokines than
stromal brain cells (astrocytes). In this in vitro study, coincu-
bation of TB-infected microglial cells with dexamethasone
signiﬁcantly inhibited production of inﬂammatory media-
tors [2]. Although there has long been concern that corticos-
teroids may reduce CSF penetration of anti-TB drugs [13],
one small study demonstrated that corticosteroids had no
eﬀect on CSF penetrance of ﬁrst-line anti-TB agents [46]. A
Cochrane meta-analysis of seven randomized controlled tri-
alscomprisedatotalof1140participantsconcludedthatcor-
ticosteroidsimprovedoutcomeinHIV-negativechildrenand
adults with TBM (RR 0.78) [57]. These results were strongly
inﬂuenced by a study of 545 adults with TBM in Vietnam
showing that treatment with dexamethasone was associated
with signiﬁcantly reduced mortality at nine months of fol-
lowup [58]. One possible explanation for the survival beneﬁt
in the Vietnamese study is that the anti-inﬂammatory eﬀects
of corticosteroids reduced the number of severe adverse
events (9.5% versus 16%), particularly hepatitis, preventing
the interruption of the ﬁrst-line anti-TB drug regimen [58].
Since there are no controlled trials comparing cortico-
steroid regimens, treatment choice should be based on those
found to be eﬀective in published trials. One recommended
regimen for children is dexamethasone 12mg/day IM (8mg/
day for children weighing ≤25kg) for three weeks, followed
by gradual taper over the next three weeks [59]. In the large
study in Vietnam, patients with mild disease received intra-
venous dexamethasone 0.3mg/kg/day × 1 week, 0.2mg/kg/
day × 1 week, and then four weeks of tapering oral therapy
[58]. For patients with more severe TBM, intravenous dex-
amethasone was given for four weeks (1 week each of 0.4mg/
kg/day, 0.3mg/kg/day, 0.2mg/kg/day, and 0.1mg/kg/day),4 Tuberculosis Research and Treatment
Table 1: Recommended standard treatment regimen for drug-susceptible TBM.
Treatment phase and
anti-TB agent
Recommended dose
(mg/kg/day) Maximum dose (mg/day) Potential side eﬀects Duration of treatment
Isoniazid 5–10 300 hepatotoxicity peripheral
neuropathy Minimum of 9 months
Rifampin 10 450 (<50kg)
600 (≥50kg)
hepatotoxicity, rash, ﬂu-like
syndrome, and multiple drug
interactions.
Minimum of 9 months
Pyrazinamide 25–30 1500 (<50kg)
2000 (≥50kg)
hepatotoxicity, arthralgia,
gastrointestinal upset, anorexia,
and photosensitization of the
skin
2m o n t h s
Streptomycin (IM)∗ 15 in adults
(30 in children) 1000 nephrotoxicity, ototoxicity, and
vestibular toxicity 2m o n t h s
Ethambutol∗ 15–20
1600 in adults
(1000 in HIV (−) and 2500
in HIV (+) children)
optic neuritis, peripheral
neuritis, arthralgia, and
gastrointestinal upset
2m o n t h s
∗For empiric induction treatment for presumed drug-susceptible M. tuberculosis,e i t h e rs t r e p t o m y c i no re t h a m b u t o li sr e c o m m e n d e da st h ef o u r t ha g e n t .
Table 2: Pharmacokinetic activity and CSF penetration of anti-TB
drugs.
Anti-TB drug Activity CSF
penetration
1st-line drugs
Isoniazid Cidal 90%–95%
Rifampin Cidal 5%–25%
Pyrazinamide Cidal 95%–100%
Streptomycin Static 20%–25%
Ethambutol Static 10%–50%
Ciproﬂoxacin Cidal 15%–35%
Levoﬂoxacin Cidal 60%–80%
Moxiﬂoxacin Cidal 70%–80%
2nd-line drugs
Ethionamide Cidal 80%–95%
Cycloserine Static 40%–70%
Amikacin Cidal 10%–25%
Streptomycin Cidal 10%–20%
Capreomycin Static unknown
Para-aminosalicylic acid Static unknown
Thioacetazone Static unknown
Linezolid Cidal 80%–100%
New agents Bedaquiline (TMC207) Cidal unknown
Delamanid (OPC-67683) Cidal unknown
Cidal: bactericidal,
Static: bacteriostatic.
followed by four weeks of tapering oral dexamethasone ther-
apy [58].
While neutralization of TNFα predisposes individuals to
TB including TBM [11], TNFα is also considered to play an
important role in contributing to the pathogenesis of TBM
[60–63], consistent with the aforementioned deleterious ef-
fects of the CNS inﬂammatory response. Indeed, Tsenova
et al. showed that the addition of thalidomide, a potent in-
hibitor of TNFα, to antibiotics was superior to antibiotics
alone in protecting rabbits from dying (50% reduction in
mortality) in their model of TBM [62]. In addition, there
was marked reduction in TNFα levels in both CSF and blood
as well as a decrease in leukocytosis and brain pathology in
rabbits that received thalidomide [62].
5.3. Fluid Management in TBM. In patients with TBM, there
may be nonosmotic stimuli for antidiuretic hormone (ADH)
expression, resulting in a syndrome of inappropriate ADH
(SIADH) release. While ADH itself may not aggravate cere-
bral edema, acute development of signiﬁcant hyposmotic
hyponatremiamayworsencerebraledemaduetowatershift-
ing from the intravascular compartment into the extravascu-
lar (intracellular and extracellular) space of the brain. While
restriction of water intake is a mainstay of SIADH treatment,
hypovolemia should be avoided, since it may decrease cere-
bral perfusion as well as serve as a stimulusfor further ADH
release. In a comprehensive review of this issue, it was noted
t h a tﬂ u i dr e s t r i c t i o nt op r e v e n tc e r e b r a le d e m ai nT B Mi s
unjustiﬁed [64]. Instead, it was recommended that a euv-
olemic state should be the goal to maintain cerebral perfu-
sion as well as to prevent hypovolemia-induced ADH release.
If symptomatic, acute hyponatremia does not respond to
anti-TB treatment and appropriate ﬂuid restriction (while
maintaining euvolemia), use of V2 (ADH) receptor antag-
onist should be considered although, to the best of our
knowledge, this has not been studied in TBM. Care must be
taken, however, to prevent too rapid of correction of chronic
hyponatremia due to the risk of precipitating osmotic demy-
elination syndrome.
5.4. Surgical Intervention in TBM Hydrocephalus. Hydro-
cephalus is a common complication of TBM; prevalence has
been documented in >75% of patients in several published
series [65, 66]. Ventriculoperitoneal shunt placement and
endoscopic third ventriculostomy are surgical techniques
which have been demonstrated to relieve elevated intracra-
nial pressure (ICP) in TBM, leading to improved neuro-
logical outcomes [67, 68]. Children are at particularly highTuberculosis Research and Treatment 5
risk for hydrocephalus and elevated ICP. In a study of 217
childrenwithTBMinSouthAfrica,30%requiredventriculo-
peritoneal shunting for either noncommunicating hydro-
cephalus or failure of medical therapy with diuretics in com-
municating hydrocephalus [69]. Historically, surgical inter-
vention was only recommended with grade 2 or 3 TBM
hydrocephalus (normal or mildly altered sensorium; easily
arousable) due to increased mortality and risk of poor sur-
gical outcome in patients with grade 4 disease (deeply coma-
tose). However, a retrospective analysis of 95 patients with
grade 4-associated hydrocephalus who underwent shunt
placement demonstrated favorable outcomes in 33%–45%
of patients, suggesting that there may be a role for surgical
intervention even in advanced TBM hydrocephalus [70]. In
thisstudy,poorneurologicaloutcomesaftershuntplacement
were associated with age < three years and > three days in
duration of symptoms.
5.5. Treatment Issues of TBM in Patients with Concurrent HIV
Infection. TBisthemostcommonopportunistic infectionin
HIV-infected persons, and HIV infection is an independent
risk factor for extrapulmonary TB including meningitis [71].
For these reasons, diagnosis of TBM should automatically
trigger testing for HIV infection. In general, the diagnosis
and treatment of TBM in HIV-infected individuals is similar
in principle to non-HIV infected subjects although there are
a few notable caveats, including the potential development
of immune reconstitution inﬂammatory syndrome (IRIS),
drug interactions and toxicities with concomitant anti-TB
andantiretroviral(ARV)therapy,questionableeﬃcacyofad-
junctive corticosteroids, and higher prevalence of drug-re-
sistant TB in HIV-positive populations.
Treatment of HIV with ARV therapy can result in IRIS,
causing clinical exacerbation of TBM. Indeed, in high HIV
prevalent settings, CNS TB complicated by IRIS has been
shown to be the most frequent cause for neurological dete-
rioration in patients newly starting ARV therapy [72]. Risk
factors for IRIS include a high pathogen load (e.g., miliary
TB), very low CD4 T-cell count (<50 cells/μL) when ARV
therapy is initiated [73], and concurrent initiation of ARV
and anti-TB therapy [74].
Concurrent ARV and anti-TB therapy carries the risk
of drug interactions and toxicities. However, delaying ARV
therapy in patients coinfected with HIV and TB has been as-
sociated with higher mortality [75]. Nevertheless, due to the
possibility of IRIS with ARV initiation, most guidelines do
not recommend simultaneous initiation of ARV and anti-TB
medications. A recent randomized controlled trial compar-
ing mortality in patients started on immediate ARV at the
time of diagnosis of TBM and HIV versus patients started
on ARV two months after diagnosis found signiﬁcantly more
serious adverse events in the immediate arm [74]. Mortality
did not diﬀer signiﬁcantly, but there was a trend towards
greater all-cause mortality in the immediate ARV group at
nine months followup. The World Health Organization rec-
ommends that anti-TB therapy be started ﬁrst, followed by
ARV treatment within eight weeks [34]. The Center for Dis-
ease Control and Prevention recommends that for patients
with CD4 counts <100 cells/μL, ARV therapy be started after
two weeks of anti-TB therapy [76].
T h eb e n e ﬁ to fa d j u n c t i v ec o r t i c o s t e r o i dt r e a t m e n tf o r
TBM in patients coinfected with HIV has not been demon-
strated [71]. In the large study of Vietnamese adults with
TBM, no mortality beneﬁt from dexamethasone was found
in the subgroupof 98 patients whowere coinfectedwith HIV
[58]. Thus, at the present time, the beneﬁt of adjunctive cor-
ticosteroid treatment in HIV-infected individuals remains
uncertain [57] although the theoretical beneﬁt of corticos-
teroids to decrease TB-associated IRIS has led some experts
to prescribe them to this population.
Thereisalsoevidencethataparticularlyvirulentstrainof
TB, the W-Beijing genotype, is associated with HIV infection
and high levels of resistance in TBM [77]. Multiple studies
have shown MDR-TB to be more commonly found in HIV-
infected patients with concurrent TBM [78–80], often lead-
ing to treatment failure and very high mortality. In high HIV
prevalence settings and in all HIV-infected patients, daily
anti-TB treatment as directly observed therapy should be
given in order to reduce relapse and treatment failure [34,
81]. It is important to note that HIV coinfection alone, even
withoutTBdrugresistance,confersworseoutcomesinTBM.
HIV coinfection was shown to be associated with 3.5 times
higher mortality in a retrospective cohort study of TBM
patients in the United States from 1993–2005 [19].
6.Prognosis
PrognosisofTBMlargelydependsonneurologicstatusatthe
timeofpresentation,andtime-to-treatmentinitiation.While
the course of TBM is generally not as rapid or fulminant
as meningitis due to pyogenic bacteria, empiric treatment
should be initiated as soon as the diagnosis is suspected as
any delay in treatment can worsen outcome. Various case se-
ries indicate a mortality rate of 7%–65% in developed coun-
t r i e s ,a n du pt o6 9 %i nu n d e r d e v e l o p e da r e a s[ 3–5]. Mor-
tality risk is highest in those with comorbidities, severe neu-
rologic involvement on admission, rapid progression of dis-
ease, and advanced or very young age. Neurologic sequelae
occur in up to 50% of survivors [5].
7.AnimalModelsAreNeededtoAdvanceOur
Understandingand Treatmentof TBM
Animal models are critically important in testing the eﬃcacy
of new drugs and vaccines against TB [82]. The challenge of
animal models of TBM is that TBM in humans is considered
to typically occur a certain period of time after a primary
infection through the respiratory tract, a condition that
would be diﬃcult to mimic in experimental animals. Indeed,
all animal models of TBM resort to direct inoculation of
M. tuberculosis into the CNS. The rabbit model of TBM, in
which mycobacteria are inoculated directly into the cisterna
magna, is perhaps the most well-established animal model
of TBM [8, 62]. Therapeutic studies examining eﬃcacy of
antibiotics, vaccines, and adjunctive agents such as thalido-
mide in the context of TBM have been studied in the rabbit6 Tuberculosis Research and Treatment
model [62, 83, 84]. While the murine model of TB is more
tractable than rabbits due to the greater variety of mouse
reagents available and lower cost in conducting the studies,
the immunologic and clinical responses of mice to experi-
mental TBM do not mimic as well as rabbits to human TBM
[85].
Despite the fact that BCG vaccination is suboptimal in
protecting against pulmonary TB [86, 87], it is considered
to be relatively eﬃcacious in protecting against childhood
TBM [88]. Tsenova et al. showed in a rabbit model of TBM
that while BCG provided protection against the laboratory
strain M. tuberculosis H37Rv, it aﬀorded signiﬁcantly less
protection against a hypervirulent clinical strain (W-Beijing
HN878), particularly against CNS disease [84]. In BCG-vac-
cinated mice challenged with W-Beijing HN878, there was
signiﬁcantly greater inﬁltration of the subarachnoid space
by lymphocytes and macrophages, coincident with greater
bacterial burden and worse CNS pathology score [84]. An
important lesson from this study is that in the search for
more eﬃcacious TB vaccines, it is important to test the vac-
cine in animals challenged with relevant, clinical strains of
M. tuberculosis.
8. Conclusion
Meningitis is the most deadly form of TB, particularly in
persons coinfected with HIV. Early diagnosis and treatment
can dramatically reduce the high mortality associated with
this disease. In general, treatment should be at least nine
months in duration and should be comprised of at least four
agents to which the M. tuberculosis strain has known or sus-
pected susceptibilities. Adjunctive corticosteroid treatment
should be considered, particularly in persons without con-
currentHIVinfection.Inordertoguidetherapy,itisoptimal
to base treatment on TB resistance patterns, especially in
HIV-coinfected persons who carry high risk for drug-resist-
ant TB. More studies are needed to evaluate CSF penetration
of newer TB agents to facilitate development of better treat-
ment regimens for both drug-susceptible and drug-resistant
TBM. Additionally, randomized controlled trials to optimize
treatment for MDR-TBM are important to ﬁnd the best
possible combination of drugs available and to standardize
treatment.
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